Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Addex Therapeutics Ltd ADR (ADXN)
Addex Therapeutics Ltd ADR (ADXN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 14,530
  • Shares Outstanding, K 12,858
  • Annual Sales, $ 3,190 K
  • Annual Income, $ -16,800 K
  • 60-Month Beta 1.89
  • Price/Sales 5.56
  • Price/Cash Flow N/A
  • Price/Book 1.49
Trade ADXN with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -3.54
  • Most Recent Earnings -0.56 on 11/11/22
  • Next Earnings Date 03/30/23
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.83
  • Growth Rate Est. (year over year) +120,461.45%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8900 +8.99%
on 03/13/23
2.2800 -57.46%
on 03/01/23
-1.0800 (-52.68%)
since 02/28/23
3-Month
0.5950 +63.03%
on 12/30/22
2.2800 -57.46%
on 03/01/23
+0.3700 (+61.67%)
since 12/28/22
52-Week
0.5500 +76.36%
on 12/22/22
5.4500 -82.20%
on 04/22/22
-3.3000 (-77.28%)
since 03/28/22

Most Recent Stories

More News
Addex Therapeutics Ltd. Sponsored ADR (ADXN) Reports Q3 Loss, Tops Revenue Estimates

Addex Therapeutics Ltd. Sponsored ADR (ADXN) delivered earnings and revenue surprises of 0% and 87.13%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead...

ADXN : 0.9700 (-14.16%)
ALPN : 7.49 (-7.13%)
Aclaris Therapeutics (ACRS) Reports Q3 Loss, Tops Revenue Estimates

Aclaris (ACRS) delivered earnings and revenue surprises of 23.08% and 1,083.45%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

ACRS : 8.33 (+0.97%)
ADXN : 0.9700 (-14.16%)
Corbus Pharmaceuticals (CRBP) Reports Q2 Loss, Lags Revenue Estimates

Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of -16.67% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

CRBP : 8.83 (+9.69%)
ADXN : 0.9700 (-14.16%)
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Misses Revenue Estimates

Aclaris (ACRS) delivered earnings and revenue surprises of 13.89% and 4.14%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

ACRS : 8.33 (+0.97%)
ADXN : 0.9700 (-14.16%)
ImmunoGen (IMGN) Reports Q2 Loss, Lags Revenue Estimates

ImmunoGen (IMGN) delivered earnings and revenue surprises of -9.09% and 16.74%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

IMGN : 3.71 (-3.13%)
ADXN : 0.9700 (-14.16%)
Addex Completes $4.2 Million Equity Financing

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 26, 2022 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage...

ADXN : 0.9700 (-14.16%)
Addex (ADXN) Terminates Parkinson's-Related Dyskinesia Study

Addex (ADXN) terminates the phase IIb/III study evaluating dipraglurant as a potential treatment for dyskinesia associated with Parkinson's disease. Shares fall.

JNJ : 153.43 (+0.08%)
LPTX : 0.3276 (+0.15%)
DTIL : 0.7020 (-7.39%)
ADXN : 0.9700 (-14.16%)
Addex Shareholders Approve All Resolutions at Annual General Meeting

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 10, 2022 – Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company...

ADXN : 0.9700 (-14.16%)
Addex Therapeutics Ltd. Sponsored ADR (ADXN) Reports Q1 Loss, Misses Revenue Estimates

Addex Therapeutics Ltd. Sponsored ADR (ADXN) delivered earnings and revenue surprises of -86.54% and 49.61%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead...

ADXN : 0.9700 (-14.16%)
PRPH : 7.46 (-3.74%)
Addex Reports Q1 2022 Financial Results

CHF14.9M ($16.1M) of cash and cash equivalents at March 31, 2022Dipraglurant Phase 2 blepharospasm clinical trial on track to report data in Q2 2022Phase...

ADXN : 0.9700 (-14.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Addex Therapeutics Ltd is a clinical-stage pharmaceutical company. It is focused on the development and commercialization of small molecule drugs for neurological disorders. The company's lead drug candidate includes dipraglurant, ADX71149 which are in clinical stage. Its Preclinical programs include...

See More

Key Turning Points

3rd Resistance Point 1.2767
2nd Resistance Point 1.1933
1st Resistance Point 1.0817
Last Price 0.9700
1st Support Level 0.8867
2nd Support Level 0.8033
3rd Support Level 0.6917

See More

52-Week High 5.4500
Fibonacci 61.8% 3.5782
Fibonacci 50% 3.0000
Fibonacci 38.2% 2.4218
Last Price 0.9700
52-Week Low 0.5500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar